Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Leisha A. Emens(Johns Hopkins University), Francesco M. Marincola(Center for Translational Molecular Medicine), Barbara Seliger(Luther University), William L. Redmond(Providence St. Vincent Medical Center), Alexander M.M. Eggermont(University Medical Center Utrecht), Phillip K. Darcy(Peter MacCallum Cancer Centre), Sandra Demaria(Cornell University), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 565
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k